Thursday, February 18, 2021

What good journalism does

"Revealed: chemicals giant sold Louisiana plant amid fears over cost of offsetting toxic emissions"

"Chemicals giant DuPont decided to sell a plant in south Louisiana that emits a likely cancer causing pollutant, citing “major concerns” that government agencies would regulate its emissions to protect the community living nearby, internal documents seen by the Guardian reveal.

The documents show the multibillion-dollar company worried in 2011 about the potential cost of offsetting its emissions of the “likely human carcinogen”, chloroprene, and so moved to sell the plant, the Pontchartrain Works facility.

The company codenamed the sale “Project Elm” in an apparent bid to keep the deal, completed in 2015, secretive. It is also alleged the company withheld details of its own research to offset emissions from the plant’s new owners."
Continue reading the article online (subscription may be required)
https://www.theguardian.com/us-news/2021/feb/17/revealed-chemicals-dupont-giant-sold-louisiana-plant-fears-offsetting-toxic-emissions

"Fake Doctors, Fake Documents: How a Russian Doping Lie Fell Apart"
"If the cover-up was to work, the high jumper Danil Lysenko realized far too late, he had better familiarize himself with the Moscow hospital where Russian track and field officials had insisted he had undergone a battery of medical tests.

The details mattered. The tests were the centerpiece of Russia’s explanation for why antidoping officials had been unable to locate Lysenko in the spring of 2018.

The punishment mattered, too: Athletes found guilty of so-called whereabouts failures — effectively failing to make themselves available for random drug tests — can face suspensions of up to two years. Those caught lying, falsifying documents or obstructing investigators risked even worse. Either sanction, though, would most likely keep Lysenko, a talented high jumper who has just turned 21, from representing Russia at the Tokyo Olympics."
Continue reading the article online (subscription may be required)
 
 

No comments:

Post a Comment